SEC23A Gene Expression and Prognostic Data for Gastric Cancer

A research article analyzing SEC23A gene expression in gastric cancer cohorts from The Cancer Genome Atlas and other public databases. The study, authored by Liang Li and last updated in April 2026, investigates the gene's role as a prognostic indicator and its correlation with tumor immune microenvironment and drug sensitivity. The findings are based on bioinformatics analysis and in vitro validation.

Use Cases

• Identify prognostic biomarkers for gastric cancer based on SEC23A expression levels described in the study.
• Analyze correlations between gene expression and tumor immune microenvironment features, such as M2 macrophage infiltration.
• Predict patient sensitivity to immunotherapy (anti-PD-1/CTLA-4) and small-molecule inhibitors based on SEC23A expression.
• Validate gene function through in silico analysis of public cohorts like TCGA and GEO as referenced in the methods.

Strengths

• Data is sourced from authoritative public repositories like The Cancer Genome Atlas and Gene Expression Omnibus.
• The study includes validation through in vitro functional assays on cell proliferation.
• The dataset is licensed under CC-BY-4.0, allowing for open reuse.

Limitations

• The primary data file is a 2.1 MB PDF, which may require extraction of underlying data for computational analysis.
• Row count and column-level documentation for any underlying data are unknown.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Bioinformatics analysis of public cancer genomics cohorts and in vitro validation.

Time Range

null

Freshness

Last updated 2026-04-13 04:35:30; freshness should be verified.

Geography

null